



1653  
IDS/ #3  
1/8/02

PATENT CASE IN01159K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

A. Saksena *et al.*

Serial No.:09/908,955

Filed: July 19, 2001

) Examiner: Not assigned yet  
Group Art Unit: Not assigned yet  
Atty. Docket No.: IN01159K

For: **NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900  
JAN 04 2002

RECEIVED

**INFORMATION DISCLOSURE STATEMENT**

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145  
WO 89/04669  
WO 98/17679  
WO 98/22496  
WO 99/07734  
WO 00/09558  
WO 00/09543  
EP 381 216

Publications:

Pizzi *et al.* (1994) Proc. Natl. Acad. Sci (USA) 91:888-892  
Failla *et al.* (1996) Folding & Design 1:35-42  
Kollykhalov *et al.* (1994) J. Virol. 68:7525-7533  
Komoda *et al.* (1994) J. Virol. 68:7351-7357  
Landro *et al.* (1997) Biochem. 36:9340-9348  
Ingallinella *et al.* (1998) Biochem. 37:8906-8914  
Llinàs-Brunet *et al.* (1998) Bioorg. Med. Chem. Lett. 8:1713-1718  
Martin *et al.* (1998) Biochem. 37:11459-11468  
Dimasi *et al.* (1997) J. Virol. 71:7461-7469  
Martin *et al.* (1997) Protein Eng. 10:607-614  
Elzouki *et al.* (1997) J. Hepat. 27:42-48  
BioWorld Today 9(217): 4 (November 10, 1998)  
Berenguer *et al.* (1998) Proc. Assoc. Am. Physicians 110(2):98-112  
Hoofnagle *et al.* (1997) N. Engl. J. Med. 336:347  
R. Zhang *et al.*, Analytical Biochemistry, 270 (1999) 268-275

D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401  
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520  
K. Holmberg *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412  
A. Marchetti *et al*, *Synlett.*, S1 (1999) 1000-1002  
W. Han *et al*, *Bioorganic & Biomedicinal Chem Lett.*, 10 (2000) 711-713  
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4, Part 2, October 1999), Abstract No. 615 (Proceedings of AASLD 50<sup>th</sup> Annual Meeting, Dallas, Texas, November 5-9, 1999.  
L. Hughes, *Org. Reactions*, 42 (1992) 335.  
R. F. Heck, *Org. Reactions*, 27 (1989) 345-390.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

December 19, 2001  
Schering-Plough Corporation  
2000 Galloping Hill Road  
Patent Department, K-6-1,1990  
Kenilworth, NJ 07033  
Tel: (908) 298-5068  
Fax: (908) 298-5388

Respectfully submitted,




Palaiyur S. Kalyanaraman  
Attorney for Applicants  
Reg. No. 34,634

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on

December 19, 2001

Palaiyur S. Kalyanaraman  
Registered Representative



12/19/2001

Signature and Date of Signature



IDS/##  
1/8/02  
653

PATENT CASE IN01158K

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

A. Saksena *et al.*

Serial No.:09/909,012

Filed: July 19, 2001

)  
Examiner: Not assigned yet  
)  
Group Art Unit: Not assigned yet  
)  
Atty. Docket No.: IN01158K

For: **NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF  
HEPATITIS C VIRUS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

JAN 07 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

**Documents cited in the Application:**

U.S. 5,712,145  
WO 89/04669  
WO 98/17679  
WO 98/22496  
WO 99/07734  
WO 00/09558  
WO 00/09543  
EP 381 216

**Publications:**

Pizzi *et al.* (1994) Proc. Natl. Acad. Sci (USA) 91:888-892  
Failla *et al.* (1996) Folding & Design 1:35-42  
Kollykhalov *et al.* (1994) J. Virol. 68:7525-7533  
Komoda *et al.* (1994) J. Virol. 68:7351-7357  
Landro *et al.* (1997) Biochem. 36:9340-9348  
Ingallinella *et al.* (1998) Biochem. 37:8906-8914  
Llinàs-Brunet *et al.* (1998) Bioorg. Med. Chem. Lett. 8:1713-1718  
Martin *et al.* (1998) Biochem. 37:11459-11468  
Dimasi *et al.* (1997) J. Virol. 71:7461-7469  
Martin *et al.* (1997) Protein Eng. 10:607-614  
Elzouki *et al.* (1997) J. Hepat. 27:42-48  
BioWorld Today 9(217): 4 (November 10, 1998)  
Berenguer *et al.* (1998) Proc. Assoc. Am. Physicians 110(2):98-112  
Hoofnagle *et al.* (1997) N. Engl. J. Med. 336:347  
R. Zhang *et al.*, Analytical Biochemistry, 270 (1999) 268-275

D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401  
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520  
K. Holmberg *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412  
A. Marchetti *et al*, *Synlett.*, S1 (1999) 1000-1002  
W. Han *et al*, *Bioorganic & Biomedicinal Chem Lett.*, 10 (2000) 711-713  
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4, Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50<sup>th</sup> Annual Meeting, Dallas, Texas, November 5-9, 1999).  
L. Hughes, *Org. Reactions*, 42 (1992) 335.  
R. F. Heck, *Org. Reactions*, 27 (1989) 345-390.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

Respectfully submitted,


December 19, 2001  
Schering-Plough Corporation  
2000 Galloping Hill Road  
Patent Department, K-6-1, 1990  
Kenilworth, NJ 07033  
Tel: (908) 298-5068  
Fax: (908) 298-5388

  
Palaiyur S. Kalyanaraman  
Attorney for Applicants  
Reg. No. 34,634

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on

December 20, 2001

Palaiyur S. Kalyanaraman  
Registered Representative

 12/20/01

Signature and Date of Signature



Sheet 1 of 1

FORM PTO-1449

U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:	SERIAL NO.:
IN01158K	09/909,012
APPLICANT:	
SAKSENA, et al	

FILING DATE: July 19, 2001

GROUP: To Be Assigned

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	U.S. 5,712,145					
AB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AC	WO 89/04669					RECEIVED
AD	WO 98/17679					
AE	WO 98/22496					
AF	WO 98/07734					
AG	WO 00/09558					
AH	WO 00/09543					
AI	EP 381 216					
AJ						
AK						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	Pizzi, (1994) Proc. Natl. Acad. Sci(USA) 91:888-892
AM	Failla (1996) folding & Design 1:35-42
AN	Kollykhalov (1994) J. Virol. 68:7525-7533
AO	Komoda (1994) J. Virol. 68:7351-7357
AP	Landro (1997) Biochem 36:9340-9348
AQ	Ingallinella (1998) Biochem 37:8906-8914
AR	Llinas-Brunet (1998) Bioorg. Med. Chem. Lett, 8:1713-1718
AS	Martin (1998) Biochem 37:11459-11468
AT	Dimasi (1997) J. Virol. 71:7461-7469
AU	Martin (1997) Protein Eng. 10:607-614
AV	Elzouki (1997) J. Hepat. 27:42-48
AW	Bio World Today 9(217): 4 (November 10, 1998)
AX	Berenguer (1998) Proc. Assoc. Am. Physicians 110(2): 98-112
AY	Hoofnagle (1997) New England Journal Med. 336:347
AZ	Zhang (1999) Analytical Biochemistry 270:268-275
BA	Sali (1998) Biochemistry 33:92-3401
BB	Barlos (1991) Int. J. Pept. Protein Res 513-520
BC	Holmberg (1979) Acta Chem. Scand., B33:410-412
BD	Agrawal(1999) Hepatology Supplement to Vol 30 "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay"
BE	Hughes (1992) Org. Reactions 42:335
BF	Heck (1989) Org. Reactions 27:345-390
BG	Han, (2000) Bioorganic & Medicinal Chemistry Letters 10 "α-Ketoamides, α-Ketoesters and α-Ketones as HCV NS3 Protease Inhibitors" pp. 711-713.
BH	Marchetti(1999) Synlett, Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease", pp 1000-1002.

DATE CONSIDERED

EXAMINER

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.